ID: ALA3608814
Chembl Id: CHEMBL3608814
PubChem CID: 122187134
Max Phase: Preclinical
Molecular Formula: C21H17ClN2O2
Molecular Weight: 364.83
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOC(=O)c1cc2c3ccccc3n(Cc3ccc(Cl)cc3)c2cn1
Standard InChI: InChI=1S/C21H17ClN2O2/c1-2-26-21(25)18-11-17-16-5-3-4-6-19(16)24(20(17)12-23-18)13-14-7-9-15(22)10-8-14/h3-12H,2,13H2,1H3
Standard InChI Key: SWIGZWPZQNNDDF-UHFFFAOYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 364.83 | Molecular Weight (Monoisotopic): 364.0979 | AlogP: 5.07 | #Rotatable Bonds: 4 |
| Polar Surface Area: 44.12 | Molecular Species: NEUTRAL | HBA: 4 | HBD: ┄ |
| #RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: ┄ | CX Basic pKa: 1.96 | CX LogP: 4.97 | CX LogD: 4.97 |
| Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.47 | Np Likeness Score: -0.99 |
| 1. Chen YF, Lin YC, Chen JP, Chan HC, Hsu MH, Lin HY, Kuo SC, Huang LJ.. (2015) Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents., 25 (18): [PMID:26235951] [10.1016/j.bmcl.2015.07.058] |
Source(1):
